



**Michael Murphy
President and CEO
Gentris Corporation**

Mr. Murphy is the President and CEO of Gentris Corporation, a clinical pharmacogenomics testing and diagnostic products company based in Research Triangle Park, North Carolina.

Mr. Murphy is considered an industry pioneer and thought leader with more than 22 years of scientific and business experience in the field of pharmacogenomics. Prior to starting Gentris in 2001, Michael founded Intek Labs, the first international pharmacogenomics company. He has also held senior management positions with PPGx and Clingenix, Inc.

Mr. Murphy is actively involved in a number of industry organizations across the country providing recommendations and industry insight on regulatory and reimbursement issues. He is a frequent lecturer and author on pharmacogenomic topics and currently sits on the editorial review board of the journal, *Pharmacogenomics*. He is a member of the Pharmacogenomics Working Group (PWG), a working committee of the American Association of Clinical Chemistry (AACC). This group has been tasked with drafting some important PGx guidance documents on specific tests that are being used or poised for use in clinical laboratories – TPMT and CYP450 2D6. Mr. Murphy actively works to develop relevant topics and speakers for upcoming AACC events that address clinical laboratorians.

Mr. Murphy is active and highly regarded in the Research Triangle Park entrepreneurial community providing instruction and guidance to numerous life science companies. He is currently on the planning committee for the Council for Entrepreneurial Development's (CED) 2006 BioTech Forum. Representing over 1,000 companies, the CED is the largest entrepreneurial support organization in the nation.

Mr. Murphy received his B.S. and M.S. degrees from San Diego State University and was trained in molecular biology at the Salk Institute.

**Gentris Corporation
Morrisville, North Carolina
919.465.0100**